UK coronavirus vaccine prompts immune response in early test

UK coronavirus vaccine prompts immune response in early test

A vaccine being developed by AstraZeneca and the Oxford University appears to be safe, early-stage clinical trials have shown and it induced a strong antibody and T cell immune response among participants. The vaccine triggered a T Cell response within 14 days of vaccination and an antibody response within 28 days. Phase 2 and 3 trials for the project kicked off in May.

Kathy
Kathy
Top in Business
Get the App